代谢相关脂肪性肝病发病机制研究现状
Current Research Status on the Pathogenesis of Metabolic Dysfunction-Associated Fatty Liver Disease
DOI: 10.12677/acm.2025.15123656, PDF,    科研立项经费支持
作者: 张月婷, 罗华丽*：重庆医科大学中医药学院，重庆；黄 祎：重庆市中医院肝病科，重庆
关键词: 代谢相关脂肪性肝病；非酒精性脂肪性肝病；发病机制；Metabolic Dysfunction-Associated Fatty Liver Disease； Non-Alcoholic Fatty Liver Disease； Pathogenesis
摘要: 非酒精性脂肪性肝病(non-alcoholic liver disease, NAFLD)是一种以肝内脂质沉积为特征的慢性肝病，已正式更名为代谢相关脂肪性肝病(metabolic dysfunction-associated fatty liver disease, MAFLD)。本文旨在介绍MAFLD的发病机制，以期为临床对MAFLD的治疗拓展新思路。
Abstract: Non-alcoholic liver disease (NAFLD), characterized by the accumulation of lipids within the liver, has officially been renamed metabolic dysfunction-associated fatty liver disease (MAFLD), a chronic liver condition. This article aims to elucidate the pathogenesis of MAFLD, thereby providing novel insights into clinical treatments for this disease.
文章引用：张月婷, 黄祎, 罗华丽. 代谢相关脂肪性肝病发病机制研究现状[J]. 临床医学进展, 2025, 15(12): 2302-2308. https://doi.org/10.12677/acm.2025.15123656

参考文献

[1] 沈波, 陆伦根. 代谢相关脂肪性肝病/非酒精性脂肪性肝病的过去、现在和未来[J]. 胃肠病学, 2021, 26(6): 321-324.
[2] Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. [Google Scholar] [CrossRef] [PubMed]
[3] Ghazanfar, H., Kandhi, S.D., Nawaz, I., Javed, N., Abraham, M.C., Farag, M., et al. (2021) Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. Cureus, 13, e15141. [Google Scholar] [CrossRef] [PubMed]
[4] 郝琦, 卢晨霞, 李晓东. 基于口-肠-肝轴理论探讨微生物传播在代谢相关脂肪性肝病中的作用研究进展[J]. 中国全科医学, 2024, 27(26): 3320-3324.
[5] Kuchay, M.S., Choudhary, N.S. and Mishra, S.K. (2020) Pathophysiological Mechanisms Underlying MAFLD. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 14, 1875-1887. [Google Scholar] [CrossRef] [PubMed]
[6] Mansouri, A., Gattolliat, C.H. and Asselah, T. (2018) Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology, 155, 629-647. [Google Scholar] [CrossRef] [PubMed]
[7] Schwabe, R.F. and Luedde, T. (2018) Apoptosis and Necroptosis in the Liver: A Matter of Life and Death. Nature Reviews Gastroenterology & Hepatology, 15, 738-752. [Google Scholar] [CrossRef] [PubMed]
[8] Cariou, B., Byrne, C.D., Loomba, R. and Sanyal, A.J. (2021) Nonalcoholic Fatty Liver Disease as a Metabolic Disease in Humans: A Literature Review. Diabetes, Obesity and Metabolism, 23, 1069-1083. [Google Scholar] [CrossRef] [PubMed]
[9] Xian, Y.X., Weng, J.P. and Xu, F. (2020) MAFLD vs. NAFLD: Shared Features and Potential Changes in Epidemiology, Pathophysiology, Diagnosis, and Pharmacotherapy. Chinese Medical Journal, 134, 8-19. [Google Scholar] [CrossRef] [PubMed]
[10] 王玮. 非酒精性脂肪肝超声诊断与血糖血脂、体质量指数的关系[J]. 激光生物学报, 2018, 27(4): 349-353+366.
[11] 王广华. 非酒精性脂肪肝发病机制研究进展[J]. 中国康复理论与实践, 2004(4): 55-56.
[12] 秦亚君, 彭海洋, 刘彦, 龚建平. 非酒精性脂肪性肝病临床管理的研究进展[J]. 重庆医学, 2024, 53(5): 766-771.
[13] 路然, 洪天配. 脂质代谢紊乱导致非酒精性脂肪性肝病的发病机制[J]. 临床肝胆病杂志, 2015, 31(7): 1050-1054.
[14] 李春, 梅聪, 周琼, 等. 高脂饮食诱导非酒精性脂肪肝的发病机制研究[J]. 医学信息, 2022, 35(5): 83-86+90.
[15] 李轶, 尚立. 非酒精性脂肪肝病患者血清LncRNA PVT1表达水平与胰岛素抵抗及肝纤维化的相关性研究[J]. 现代检验医学杂志, 2023, 38(5): 80-85.
[16] 刘印聪, 罗金波, 张玉亭, 马秀英, 王文学, 耿嘉蔚. 肠道菌群代谢产物在非酒精性脂肪性肝病发病中的作用机制研究进展[J]. 山东医药, 2023, 63(5): 103-106.
[17] Kuraji, R., Sekino, S., Kapila, Y. and Numabe, Y. (2021) Periodontal Disease-Related Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Emerging Concept of Oral‐Liver Axis. Periodontology 2000, 87, 204-240. [Google Scholar] [CrossRef] [PubMed]
[18] 谢娇娇, 王莉, 何燕芳. 代谢相关脂肪性肝病的发病机制及其与肠道真菌群关系的研究进展[J]. 中国临床新医学, 2022, 15(8): 765-769.
[19] Kirpich, I.A., Marsano, L.S. and McClain, C.J. (2015) Gut-Liver Axis, Nutrition, and Non-Alcoholic Fatty Liver Disease. Clinical Biochemistry, 48, 923-930. [Google Scholar] [CrossRef] [PubMed]
[20] 赵红, 谢雯. 非酒精性脂肪性肝病的中西医结合治疗现状[J]. 中国临床医生杂志, 2020, 48(1): 16-18.
[21] Kolodziejczyk, A.A., Zheng, D., Shibolet, O. and Elinav, E. (2018) The Role of the Microbiome in NAFLD and NASH. EMBO Molecular Medicine, 11, e9302. [Google Scholar] [CrossRef] [PubMed]
[22] 赵丽, 罗娟, 陈晶. 肠道微生物群与非酒精性脂肪性肝病的最新研究进展[J]. 胃肠病学和肝病学杂志, 2020, 29(6): 700-703.
[23] 王海燕, 李裕霖, 胡静娴, 周皓, 蒋淼, 张绍仁. GO-CoA-Tat改善脂肪肝小鼠脂质代谢和氧化应激[J]. 中国临床医学, 2023, 30(6): 965-970.
[24] 张瑞, 李荣荣, 王腊梅, 曹阳春. 氧化应激在非酒精性脂肪肝发病机制中的作用和潜在治疗靶点[J]. 动物营养学报, 2022, 34(12): 7602-7615.
[25] 叶子昊, 祝可欣, 贺宇涵, 何栋升, 张景正. 非酒精性脂肪肝的发病机制及潜在药物研究进展[J]. 河北医药, 2023, 45(22): 3484-3488.
[26] Watanabe, A., Sohail, M.A., Gomes, D.A., Hashmi, A., Nagata, J., Sutterwala, F.S., et al. (2009) Inflammasome-Mediated Regulation of Hepatic Stellate Cells. American Journal of Physiology-Gastrointestinal and Liver Physiology, 296, G1248-G1257. [Google Scholar] [CrossRef] [PubMed]
[27] 李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[28] 武苏, 郑必霞, 刘婷, 朱子阳, 顾威, 刘倩琦. 一个17β-羟类固醇脱氢酶3型缺乏症家系的HSD17B3基因变异分析[J]. 中华医学遗传学杂志, 2021, 38(8): 787-790.
[29] 谢淑雅, 曹名波. 代谢相关脂肪性肝病发病机理及治疗的研究进展[J]. 胃肠病学和肝病学杂志, 2024, 33(3): 332-335.
[30] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版) [J]. 中华肝脏病杂志, 2024, 32(5): 418-434.

为你推荐